Print Share Email Send Email Your Name (required) ! Example: John Doe Email Address (required) ! Error: Please enter a valid sender email address. Example: email@example.com CC Me Recipient Email Address (required) ! Separate multiple email address with semi-colons (up to 5). Subject Subject for your email. Message (Maximum characters: 1,000) Error: Please enter your name Error: Please enter your email address Error: Please enter a valid recipient email address. Example:firstname.lastname@example.org Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Alexander SA, Castillo JG. Alexander S.A., & Castillo J.G. Alexander, Steven A., and Javier G. Castillo. POPular Genetics: A CYP2C19 Genotype-Guided Approach to P2Y12 Inhibitor Therapy Shows Potential in Patients Undergoing PCI. Hurst's the Heart Updates, 16 October 2019. McGraw-Hill, 2019. AccessCardiology. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=506588§ionid=229608460APA Citation Alexander SA, Castillo JG. Alexander S.A., & Castillo J.G. Alexander, Steven A., and Javier G. Castillo. (2019). Popular genetics: a cyp2c19 genotype-guided approach to p2y12 inhibitor therapy shows potential in patients undergoing pci. Fuster V. Fuster V Fuster, Valentin. Hurst's the heart updates. McGraw-Hill. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=506588§ionid=229608460.MLA Citation Alexander SA, Castillo JG. Alexander S.A., & Castillo J.G. Alexander, Steven A., and Javier G. Castillo. "POPular Genetics: A CYP2C19 Genotype-Guided Approach to P2Y12 Inhibitor Therapy Shows Potential in Patients Undergoing PCI." Hurst's the Heart Updates Fuster V. Fuster V Fuster, Valentin. McGraw-Hill, 2019, https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=506588§ionid=229608460. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top POPular Genetics: A CYP2C19 Genotype-Guided Approach to P2Y12 Inhibitor Therapy Shows Potential in Patients Undergoing PCI by Steven A. Alexander, Javier G. Castillo Listen + +Update to Chapter 41: Antiplatelet and Anticoagulant Therapy in Acute Coronary Syndrome Study Summary + +Many patients have an inadequate response to clopidogrel owing to genetic variations in hepatic cytochrome P450 enzymes. In the POPular Genetics trial, a genotype-guided strategy for selecting the oral P2Y12 inhibitor was compared with standard therapy (ticagrelor or prasugrel) among patients with STEMI undergoing primary PCI. In the genotype-guided group, carriers of CYP2C19*2 or CYP2C19*3 loss-of-function alleles received ticagrelor or prasugrel (n = 1,242) and noncarriers received clopidogrel (n = 1,246). The primary combined outcome (all-cause death, myocardial infarction, stent thrombosis, stroke, or major bleeding) occurred in 5.1% of the genotype-guided group versus 5.9% of the standard of care group (P <0.001 for noninferiority). Major or minor bleeding occurred in 9.8% of the genotype-guided group and in 12.5% of the standard of care group (HR 0.78; P = 0.04) and was mainly driven by minor bleeding. Commentary + +Study Strengths: In previous trials, the definition of net clinical benefit has often included only BARC type 2 bleeding. In this study, major bleeding, which has an effect on morbidity and mortality similar to thrombotic outcomes, was included. +Study Limitations: Although a blinded independent committee adjudicated all outcomes, the trial had an open-label design. The lower than expected incidence of the primary outcome made the prespecified noninferiority margin proportionally wider with respect to the event rate in the control group. There are more polymorphisms of CYP2C19, potentially associated with increased thrombotic or bleeding risk, that were not assessed. +Next Steps/Clinical Perspective: This trial showed how genotype-guided therapy might be used to improve the risk–benefit ratio of antiplatelet therapy. However, the guidelines are unlikely to change until the results of TAILOR-PCI (genotype-guided therapy compared with standard of care > 5,000 patients with ACS or stable CAD) are released. Trial Reference + + + +Claassens DM, Vos GJ, Bergmeyer TO, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI (POPular Genetics). N. Engl. J. Med. doi: 10.1056/NEJMoa1907096.